These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12699058)

  • 21. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.
    Kumamoto H; Sasano H; Taniguchi T; Suzuki T; Moriya T; Ichinohasama R
    Pathol Int; 2001 Aug; 51(8):579-84. PubMed ID: 11564211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.
    Moelans CB; de Weger RA; van Blokland MT; Ezendam C; Elshof S; Tilanus MG; van Diest PJ
    Cell Oncol; 2009; 31(1):1-10. PubMed ID: 19096145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.
    Luftner D; Henschke P; Kafka A; Anagnostopoulos I; Wiechen K; Geppert R; Stein H; Wernecke KD; Kreienberg R; Possinger K
    Int J Biol Markers; 2004; 19(1):1-13. PubMed ID: 15077921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement.
    Bohn U; Aguiar J; Bilbao C; Murias A; Vega V; Chirino R; Díaz-Chico N; Díaz-Chico JC
    Int J Cancer; 2002 Oct; 101(6):539-44. PubMed ID: 12237894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Her-2/neu status in breast cancer metastases to the central nervous system.
    Lear-Kaul KC; Yoon HR; Kleinschmidt-DeMasters BK; McGavran L; Singh M
    Arch Pathol Lab Med; 2003 Nov; 127(11):1451-7. PubMed ID: 14567724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer.
    Valerón PF; Chirino R; Fernandez L; Torres S; Navarro D; Aguiar J; Cabrera JJ; Diaz-Chico BN; Diaz-Chico JC
    Int J Cancer; 1996 Jan; 65(2):129-33. PubMed ID: 8567106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular protocol for HER2/neu analysis in breast carcinoma].
    Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
    Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
    Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
    Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
    Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
    Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
    Lara PN; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Kauderer C; Tichauer G; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2002 May; 94(10):2584-9. PubMed ID: 12173324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay.
    Goud KI; Dayakar S; Vijayalaxmi K; Babu SJ; Reddy PV
    Indian J Med Res; 2012 Mar; 135(3):312-7. PubMed ID: 22561616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis.
    Hung TL; Chen FF; Liu JM; Lai WW; Hsiao AL; Huang WT; Chen HH; Su WC
    Clin Cancer Res; 2003 Jul; 9(7):2605-12. PubMed ID: 12855637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.